Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EHA 2021 | CAR-NK: improved CRS and promising safety profiles in myeloma

Leo Rasche • 14 Jun 2021
EHA 2021
Multiple Myeloma CAR-NK

Leo Rasche, MD, University of Arkansas for Medical Sciences, Little Rock, AR, shares an update on chimeric antigen receptor natural killer cell (CAR-NK) therapy for multiple myeloma, highlighting reduced incidences of cytokine release syndrome (CRS) and promising tolerability profiles. This interview took place at the virtual European Hematology Association (EHA) Congress 2021.

More from Leo Rasche

2:18
Evolving treatment options in NDMM: transplant-eligible and transplant-ineligible patients
Leo Rasche • 28 Sep 2023
1:47
WGS reveals sequential & persistent loss of BCMA and GPRC5D after bispecific antibodies in myeloma
Leo Rasche • 28 Sep 2023
1:02
Promising novel targets emerging in myeloma & the value of combining agents
Leo Rasche • 28 Sep 2023
9:00
Genomics in the age of I-O
Francesco Maura et al. • 26 Mar 2022

Related Videos

0:57
Overcoming barriers to treating older patients with myeloma
Sergio Giralt • 16 Apr 2024
1:01
The potentially curative role of CAR-T therapy in myeloma
Sergio Giralt • 16 Apr 2024
1:45
Expanded approval of cilta-cel in myeloma: the value of bringing CAR-T cells into earlier lines
Monika Engelhardt • 16 Apr 2024
4:59
MRD as an endpoint for accelerating drug approval in multiple myeloma: updates from the ODAC meeting
Ola Landgren • 13 Apr 2024
The content of VJHemOnc is intended for healthcare professionals